USFDA approves Inclisiran to lower LDL cholesterol
US Food and Drug Administration has approved inclisiran (Leqvio; Novartis) for lowering LDL cholesterol levels.
Inclisiran is a small interfering RNA (siRNA) therapy which has been approved as an adjunct to diet and maximally tolerated statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (FH) with LDL cholesterol levels that are still too high.
For more details, check out the full story on the link below:
FDA approves inclisiran to lower LDL cholesterol and keep it low with two doses a year
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.